The downgrade from Outperform to Market Perform by a reputable analyst, along with a drastic reduction in price target, is likely to negatively impact investor sentiment and the short-term stock price of Spruce Biosciences. The significant adjustment in the price target reflects a change in the analyst's outlook on the company's future performance, which could lead to a decrease in investor confidence and a potential sell-off.